Antworten zu den Fragen zu « Schwere Panzytopenie und Stomatitis unter low-dose-Therapie mit Methotrexat » aus Praxis Nr. 13

July 2011
Praxis (16618157);7/6/2011, Vol. 100 Issue 14, p875
Academic Journal
No abstract available.


Related Articles

  • Colchicine and toxicity.  // WHO Drug Information;2006, Vol. 20 Issue 1, p17 

    The article reports that the Medicines and Medical Devices Safety Authority in New Zealand, Medsafe, has revised the dosage advice for colchicine. According to Medsafe, colchicine is now limited to second-line treatment for acute gout. The dosing interval has increased from two-three hourly to...

  • Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Nordström, D. C.; Konttinen, L.; Korpela, M.; Tiippana-Kinnunen, T.; Eklund, K.; Forsberg, S.; Ilva, K.; Kaipiainen-Seppänen, O.; Malmi, T.; Ylä-Kerttula, T.; Honkanen, V. // Rheumatology International;Jun2006, Vol. 26 Issue 8, p741 

    To assess the performance of infliximab in a clinical setting, 364 rheumatoid arthritis (RA) patients from the National Register of Biological Treatment in Finland (ROB-FIN) were analysed. Corticosteroid usage and dose diminished ( p<0.05 and 0.001, respectively) in patients on infliximab, of...

  • Modelling the costs and effects of leflunomide in rheumatoid arthritis. Kobelt, G.; Lindgren, P.; Young, A. // European Journal of Health Economics;Sep2002, Vol. 3 Issue 3, p180 

    This study investigated the cost-effectiveness of leflunomide (LEF) compared to methotrexate (MTX) and sulfasalazine (SSZ) in the United Kingdom. A Markov model was constructed using health states defined by Health Assessment Questionnaire score. The model is based on a cohort of patients with...

  • Is Leflunomide as Safe and Effective in the Treatment of Rheumatoid Arthritis as Other DMARDs? Schooff, Michael; Wickersham, Jason // American Family Physician;9/1/2003, Vol. 68 Issue 5, p849 

    Presents a study which determined the efficacy and toxicity of leflunomide compared with placebo or other disease-modifying anti-rheumatic drugs (DMARD) in the treatment of rheumatoid arthritis. Similarity of leflunomide's efficacy and adverse events to those of methotrexate; Mechanism of...

  • Pain-medication safety.  // Consumer Reports on Health;Nov99, Vol. 11 Issue 11, p2 

    Presents a graph showing the results of toxicity tests conducted on pain medications and nonsteroidal anti-inflammatory drugs.

  • Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Cipriani, Paola; Ruscitti, Piero; Carubbi, Francesco; Pantano, Ilenia; Liakouli, Vasiliki; Berardicurti, Onorina; Giacomelli, Roberto // Clinical Rheumatology;Jan2014, Vol. 33 Issue 1, p49 

    Adult-onset Still's disease (AOSD) is a chronic inflammatory disease of unknown etiology which commonly affects young adults. Treatment of AOSD patients includes nonsteroidal anti-inflammatory drugs, corticosteroids, and DMARDs. Interleukin (IL)-6 blockade is an attractive therapeutic option for...

  • Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention. Aghajani, Mohammad Haji; Kobarfard, Farzad; Safi, Olia; Sheibani, Kourosh; Sistanizad, Mohammad // Iranian Journal of Pharmaceutical Research;2013 Supplement, Vol. 12, p169 

    To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with...

  • Aspirin Withdrawal in Acute Peptic Ulcer Bleeding: Are We Harming Patients? Barkun, Alan N.; Bardou, Marc // Annals of Internal Medicine;1/5/2010, Vol. 152 Issue 1, p52 

    The author reflects on the case for patients who developed peptic ulcer bleeding while receiving antiplatelet therapy in the U.S. Such antiplatelet therapy that was used includes low-dose aspirin or clopidegrel, which are commonly use in such case. In this connection, the author raises the...

  • Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Hanna, Elias B.; Glancy, David Luke; Saucedo, Jorge F. // Cardiovascular Drugs & Therapy;Feb2010, Vol. 24 Issue 1, p61 

    The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics